Skip to content

Kura Oncology KURA Free cash flow margin

Free cash flow margin at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
18.5%-4.3pp
Amgen logo
AmgenAMGN
23.1%-8.9pp
Exelixis logo
ExelixisEXEL
38.6%+2.9pp
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-187.2%-85.4pp
AbbVie logo
AbbVieABBV
31.8%+5.0pp
Nuvation Bio logo
Nuvation BioNUVB
-93.5%-45.2pp

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$942.78M+86.2%
Enterprise value$927.97M+95.5%
P/S13.2×+3.9×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Calculated from Kura Oncology’s reported figures.

Based on trailing twelve months.

The official record: Kura Oncology’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's free cash flow margin?
Kura Oncology (KURA) reported free cash flow margin of 130.6% in Q3 2025.
How has Kura Oncology's free cash flow margin changed year-over-year?
Kura Oncology's free cash flow margin increased by 131.2% year-over-year, from -418.8% to 130.6%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.